Definium Therapeutics (DFTX) Expected to Announce Quarterly Earnings on Thursday

Key Points

• Q1 2026 earnings due Thursday, May 7 before market — Definium is scheduled to report results and host a call at 8:00 AM ET, with analysts forecasting a loss of ($0.4780) per share for the quarter.
• Wall Street sentiment is broadly positive — the average analyst rating is "Buy" with an average target of $38.00, and several firms have higher targets (up to $70) while ratings include 3 Strong Buys, 11 Buys and 1 Sell.
• Stock and company fundamentals — DFTX opened at $20.49 (down ~3.7%), market cap ~$2.04B and a 52-week range of $6.03–$26.25; the company, renamed from Mind Medicine in Jan 2026, is advancing MM120 (Phase 3 for GAD and ADHD) and DT402 (Phase 2a for core autism symptoms).

Definium Therapeutics (NASDAQ:DFTX - Get Free Report) is expected to be issuing its Q1 2026 results before the market opens on Thursday, May 7th. Analysts expect the company to announce earnings of ($0.4780) per share for the quarter. Parties are encouraged to explore the company's upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Thursday, May 7, 2026 at 8:00 AM ET.

Definium Therapeutics Stock Down 3.7%

Definium Therapeutics stock opened at $20.49 on Thursday. The firm has a market cap of $2.04 billion, a price-to-earnings ratio of -9.62 and a beta of 2.44. The company has a debt-to-equity ratio of 0.12, a current ratio of 6.29 and a quick ratio of 6.29. Definium Therapeutics has a fifty-two week low of $6.03 and a fifty-two week high of $26.25. The firm has a fifty day moving average price of $19.53 and a two-hundred day moving average price of $15.74.

Wall Street Analysts Forecast Growth

DFTX has been the subject of a number of research analyst reports. HC Wainwright boosted their target price on shares of Definium Therapeutics from $55.00 to $70.00 and gave the stock a "buy" rating in a research report on Monday, March 2nd. Jefferies Financial Group initiated coverage on shares of Definium Therapeutics in a research report on Thursday, January 29th. They set a "buy" rating and a $30.00 target price for the company. Oppenheimer reissued an "outperform" rating and set a $40.00 target price on shares of Definium Therapeutics in a research report on Thursday, April 23rd. Piper Sandler initiated coverage on shares of Definium Therapeutics in a research report on Friday, April 10th. They set an "overweight" rating and a $49.00 target price for the company. Finally, Canaccord Genuity Group set a $38.00 target price on shares of Definium Therapeutics and gave the stock a "buy" rating in a research report on Thursday, April 16th. Three investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Buy" and an average target price of $38.00.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Cerity Partners LLC raised its position in shares of Definium Therapeutics by 2.4% during the second quarter. Cerity Partners LLC now owns 49,650 shares of the company's stock valued at $322,000 after buying an additional 1,165 shares during the last quarter. Creative Planning raised its position in shares of Definium Therapeutics by 2.6% during the second quarter. Creative Planning now owns 66,097 shares of the company's stock valued at $429,000 after buying an additional 1,655 shares during the last quarter. Russell Investments Group Ltd. raised its position in shares of Definium Therapeutics by 110.4% during the second quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company's stock valued at $25,000 after buying an additional 2,003 shares during the last quarter. Mercer Global Advisors Inc. ADV raised its position in shares of Definium Therapeutics by 10.5% during the third quarter. Mercer Global Advisors Inc. ADV now owns 21,931 shares of the company's stock valued at $259,000 after buying an additional 2,079 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its position in shares of Definium Therapeutics by 5.1% during the second quarter. JPMorgan Chase & Co. now owns 48,487 shares of the company's stock valued at $315,000 after buying an additional 2,342 shares during the last quarter. Institutional investors and hedge funds own 27.91% of the company's stock.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.